Background: The aberrant intracellular expression of a mitochondrial aspartyl-tRNA synthetase 2 (DARS2) has been reported in human cancers. Nevertheless, its critical role and detailed mechanism in lung adenocarcinoma (LUAD) remain unexplored.
Methods: Initially, The Cancer Genome Atlas (TCGA)-based Gene Expression Profiling Interactive Analysis (GEPIA) database (http://gepia.cancer-pku.cn/) was used to analyze the prognostic relevance of DARS2 expression in LUAD. Further, cell counting kit (CCK)-8, immunostaining, and transwell invasion assays in LUAD cell lines , as well as DARS2 silence on LUAD by tumorigenicity experiments in nude mice, were performed. Besides, we analyzed the expression levels of p-PI3K (phosphorylated-Phosphotylinosital3 kinase), PI3K, AKT (Protein Kinase B), p-AKT (phosphorylated-Protein Kinase B), PCNA (proliferating cell nuclear antigen), cleaved-caspase 3, E-cadherin, and N-cadherin proteins using the Western blot analysis.
Results: LUAD tissues showed higher DARS2 expression compared to normal tissues. Upregulation of DARS2 could be related to Tumor-Node-Metastasis (TNM) stage, high lymph node metastasis, and inferior prognosis. DARS2 silence decreased the proliferation, migration, and invasion abilities of LUAD cells. In addition, the DARS2 downregulation decreased the PCNA and N-cadherin expression and increased cleaved-caspase 3 and E-cadherin expressions in LUAD cells, coupled with the inactivation of the PI3K/AKT signaling pathway. Moreover, DARS2 silence impaired the tumorigenicity of LUAD . Interestingly, let-7b-5p could recognize DARS2 through a complementary sequence. Mechanistically, the increased let-7b-5p expression attenuated the promo-oncogenic action of DARS2 during LUAD progression, which were inversely correlated to each other in the LUAD tissues.
Conclusion: In summary, let-7b-5p downregulated DARS2 expression, regulating the progression of LUAD cells by the PI3K/AKT signaling pathway.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10865744 | PMC |
| http://dx.doi.org/10.32604/or.2023.030293 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of , , and in determining the prognosis of patients with lung adenocarcinoma.
Transl Lung Cancer Res
October 2024
Center of Laboratory Medicine, Qilu Hospital of Shandong University (Qingdao), Qingdao, China.
Background: Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancers, and is the leading cause of tumor-related death. Lung adenocarcinoma (LUAD) is the most prevalent subtype of NSCLC. Although significant progress of LUAD treatment has been made under multimodal strategies, the prognosis of advanced LUAD is still poor due to recurrence and metastasis.
View Article and Find Full Text PDFBasal cell carcinoma (BCC) is a slowly progressive, locally aggressive and rarely metastasizing cancer, and although its mortality is low, its morbidity and cost of disease are high. While BCC is more common, cutaneous malignant melanoma (CMM) is significant due to its higher mortality rate. These patients can be treated, but recurrence, metastasis and mortality may occur in such patients.
View Article and Find Full Text PDFMachine learning and experimental validation of novel biomarkers for hypertrophic cardiomyopathy and cancers.
J Cell Mol Med
August 2024
Cardiovascular Center, The Affiliated Hospital of Yunnan University, Yunnan University, Kunming, Yunnan, China.
Article Synopsis
- Hypertrophic cardiomyopathy (HCM) is a hereditary condition characterized by thickening of the heart muscle, contributing significantly to cardiac-related deaths, with ongoing research exploring the role of immune inflammation in its development.
- Five machine learning algorithms were used to identify five new biomarkers (DARS2, GATM, MGST1, SDSL, ARG2) linked to HCM, with GATM and MGST1 showing strong diagnostic potential based on their elevated expression in HCM tissues compared to normal tissues.
- A new risk assessment model utilizing GATM and MGST1 was developed and validated, demonstrating effective performance in distinguishing HCM patients, while also indicating these markers have prognostic relevance in both HCM and various cancers.
Targeted degradation of extracellular mitochondrial aspartyl-tRNA synthetase modulates immune responses.
Nat Commun
July 2024
Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, OH, USA.
The severity of bacterial pneumonia can be worsened by impaired innate immunity resulting in ineffective pathogen clearance. We describe a mitochondrial protein, aspartyl-tRNA synthetase (DARS2), which is released in circulation during bacterial pneumonia in humans and displays intrinsic innate immune properties and cellular repair properties. DARS2 interacts with a bacterial-induced ubiquitin E3 ligase subunit, FBXO24, which targets the synthetase for ubiquitylation and degradation, a process that is inhibited by DARS2 acetylation.
View Article and Find Full Text PDF[Expression of DARS2 in colorectal cancer and its clinical significance].
Zhonghua Bing Li Xue Za Zhi
June 2024
Department of Pathology, the First Affiliated Hospital of Nanchang University/Institute of Molecular Pathology, Nanchang University, Nanchang 330000, China.
To investigate the expression of DARS2 and its clinical significance in colorectal cancer. In this study, bioinformatics tools, especially gene expression profile interactive analysis 2 (GEPIA2), were used to conduct an in-depth analysis of DARS2 expression in colorectal cancer tissues. Immunohistochemical staining was carried out in 108 colorectal cancer specimens and 30 normal colorectal tissues obtained from the First Affiliated Hospital of Nanchang University, Nanchang, China.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!